GLP-1 receptor agonists have become a de facto aesthetic offering at many practices, driven by patient demand for weight-loss support alongside cosmetic treatment. Yet the regulatory and supply landscape remains volatile. Semaglutide and tirzepatide occupy a legal gray zone: FDA-approved for diabetes and obesity, but not for aesthetic use; subject to ongoing shortage declarations that affect compounding eligibility; and increasingly scrutinized by state boards and the FDA itself. For practice owners, the stakes are high—offering compounded GLP-1s can drive revenue and patient retention, but also exposes you to enforcement action, liability, and supply disruption. This page tracks the current status, explains the legal mechanics, and outlines what you need to verify before offering these drugs.